{"id":534115,"date":"2021-09-02T16:13:25","date_gmt":"2021-09-02T20:13:25","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"modified":"2021-09-02T16:13:25","modified_gmt":"2021-09-02T20:13:25","slug":"fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">HAMILTON<\/span>, ON\u00a0and\u00a0BOSTON, <span class=\"xn-chron\">Sept. 2, 2021<\/span> \/PRNewswire\/ &#8212; Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1196797\/Fusion_Pharmaceuticals_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1196797\/Fusion_Pharmaceuticals_Logo.jpg\" title=\"(PRNewsfoto\/Fusion Pharmaceuticals Inc.)\" alt=\"(PRNewsfoto\/Fusion Pharmaceuticals Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<ul type=\"disc\">\n<li>The Morgan Stanley 19<sup>th<\/sup> Annual Global Healthcare Conference \u2013 The fireside chat will take place on <span class=\"xn-chron\">Thursday, September 9, 2021<\/span> at <span class=\"xn-chron\">11:00am ET<\/span>. Presenting on behalf of Fusion will be Chief Executive Officer <span class=\"xn-person\">John Valliant<\/span>, Ph.D., and Chief Financial Officer <span class=\"xn-person\">John Crowley<\/span>.\n<\/li>\n<li>The H.C. Wainwright 23<sup>rd<\/sup> Annual Global Investment Conference \u2013 A recording of the presentation will be made available for on-demand viewing on <span class=\"xn-chron\">Monday, September 13<\/span>, at <span class=\"xn-chron\">7:00am ET<\/span>. Presenting on behalf of Fusion will be Chief Executive Officer <span class=\"xn-person\">John Valliant<\/span>, Ph.D.<\/li>\n<\/ul>\n<p>Webcasts of each event will be available on the &#8220;Events and Presentations&#8221; page in the &#8220;Investors &amp; Media&#8221; section of the Company&#8217;s website at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3279070-1&amp;h=1253888054&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2913436-1%26h%3D4224674445%26u%3Dhttps%253A%252F%252Fir.fusionpharma.com%252Fevents-webcasts%26a%3Dhttps%253A%252F%252Fir.fusionpharma.com%252Fevents-webcasts&amp;a=https%3A%2F%2Fir.fusionpharma.com%2Fevents-webcasts\" rel=\"nofollow noopener\">https:\/\/ir.fusionpharma.com\/events-webcasts<\/a>. Replays of the webcasts will be archived on the Company&#8217;s website for 90 days following their respective presentation dates.\u00a0\u00a0<\/p>\n<p>\n        <b>About Fusion<br \/><\/b>Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear\u2122 linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion&#8217;s lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion&#8217;s TATs and AstraZeneca&#8217;s DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck&#8217;s KEYTRUDA\u00ae (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and <span class=\"xn-location\">Hamilton, Ontario<\/span>-based <span class=\"xn-org\">McMaster University<\/span> are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company&#8217;s growing pipeline of TATs.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE95158&amp;sd=2021-09-02\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences-301368697.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences-301368697.html<\/a><\/p>\n<p>SOURCE  Fusion Pharmaceuticals Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE95158&amp;Transmission_Id=202109021610PR_NEWS_USPR_____NE95158&amp;DateId=20210902\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire HAMILTON, ON\u00a0and\u00a0BOSTON, Sept. 2, 2021 \/PRNewswire\/ &#8212; Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences. The Morgan Stanley 19th Annual Global Healthcare Conference \u2013 The fireside chat will take place on Thursday, September 9, 2021 at 11:00am ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., and Chief Financial Officer John Crowley. The H.C. Wainwright 23rd Annual Global Investment Conference \u2013 A recording of the presentation will be made available for on-demand viewing on Monday, September 13, at 7:00am ET. Presenting on behalf of Fusion will be Chief Executive Officer John &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534115","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire HAMILTON, ON\u00a0and\u00a0BOSTON, Sept. 2, 2021 \/PRNewswire\/ &#8212; Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences. The Morgan Stanley 19th Annual Global Healthcare Conference \u2013 The fireside chat will take place on Thursday, September 9, 2021 at 11:00am ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., and Chief Financial Officer John Crowley. The H.C. Wainwright 23rd Annual Global Investment Conference \u2013 A recording of the presentation will be made available for on-demand viewing on Monday, September 13, at 7:00am ET. Presenting on behalf of Fusion will be Chief Executive Officer John &hellip; Continue reading &quot;Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-02T20:13:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1196797\/Fusion_Pharmaceuticals_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2021-09-02T20:13:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":377,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1196797\\\/Fusion_Pharmaceuticals_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1196797\\\/Fusion_Pharmaceuticals_Logo.jpg\",\"datePublished\":\"2021-09-02T20:13:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1196797\\\/Fusion_Pharmaceuticals_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1196797\\\/Fusion_Pharmaceuticals_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"PR Newswire HAMILTON, ON\u00a0and\u00a0BOSTON, Sept. 2, 2021 \/PRNewswire\/ &#8212; Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will participate in two upcoming virtual investor conferences. The Morgan Stanley 19th Annual Global Healthcare Conference \u2013 The fireside chat will take place on Thursday, September 9, 2021 at 11:00am ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D., and Chief Financial Officer John Crowley. The H.C. Wainwright 23rd Annual Global Investment Conference \u2013 A recording of the presentation will be made available for on-demand viewing on Monday, September 13, at 7:00am ET. Presenting on behalf of Fusion will be Chief Executive Officer John &hellip; Continue reading \"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-02T20:13:25+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1196797\/Fusion_Pharmaceuticals_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences","datePublished":"2021-09-02T20:13:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"},"wordCount":377,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1196797\/Fusion_Pharmaceuticals_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/","name":"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1196797\/Fusion_Pharmaceuticals_Logo.jpg","datePublished":"2021-09-02T20:13:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1196797\/Fusion_Pharmaceuticals_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1196797\/Fusion_Pharmaceuticals_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fusion-pharmaceuticals-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fusion Pharmaceuticals to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534115"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534115\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}